Reglan Tardive Dyskinesia Causation: ICD-10 Code for History of Tardive Dyskinesia

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

Legacy of Accessible Health Information

This domain has a long-standing heritage of providing structured, accessible health and science information to the general public. Historically, the focus has been on broad wellness topics, leveraging public data sources and user-generated discussions to address common health concerns. This foundation has established a reliable framework for translating complex medical concepts into actionable, location-specific guidance for diverse audiences. The legacy approach emphasized broad pain points and solutions, ensuring that users could find clear, data-driven answers to their health questions. This tradition of clarity and reliability continues as we pivot to address a specific occupational exposure concern: the risk of tardive dyskinesia associated with Reglan (metoclopramide) use.

Transition to Targeted Risk Awareness

Building on our legacy of general health information, we now narrow our focus to a documented adverse effect of a commonly prescribed medication. The bridge concept here is the shift from general health information to targeted risk awareness, particularly for individuals with a history of tardive dyskinesia. This pivot requires maintaining the same structured, data-driven methodology—using location, company type, and pain point matrices—but applying it to occupational health scenarios where Reglan exposure may be a factor. The goal is to inform users about the importance of monitoring and documenting such conditions, without delving into mechanistic claims or citing external evidence, while preserving a neutral, academic tone throughout the transition.

Reglan and Tardive Dyskinesia: Mechanism and Risk

Reglan (metoclopramide) is a dopamine D2-receptor blocking agent commonly prescribed for nausea, vomiting, and gastroparesis. Its mechanism of action, while effective for gastrointestinal symptoms, carries a well-documented risk of causing tardive dyskinesia (TD), a hyperkinetic movement disorder characterized by potentially irreversible involuntary movements of the face, tongue, trunk, and extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). TD is caused by the use of dopamine receptor-blocking agents (DRBAs), a category that includes metoclopramide and antipsychotics (https://pubmed.ncbi.nlm.nih.gov/34703232/). The condition can emerge after variable exposure durations, including after a single dose in some cases (https://pubmed.ncbi.nlm.nih.gov/34712535/). The clinical presentation of TD involves involuntary, repetitive movements that may affect the face (e.g., grimacing, tongue protrusion), limbs, or trunk. These movements can be disfiguring and socially stigmatizing, and they are associated with increased comorbidities and impaired physical and mental health (https://pubmed.ncbi.nlm.nih.gov/34703232/). Once TD develops, it tends to persist despite dose adjustment or discontinuation of the causative agent (https://pubmed.ncbi.nlm.nih.gov/34703232/).

Diagnosis and ICD-10 Coding for History of Tardive Dyskinesia

The diagnosis of TD is clinical, based on characteristic movements and a history of exposure to a DRBA such as Reglan. The ICD-10 code for a history of tardive dyskinesia is G24.01, which is used to document the condition in medical records for patients who have experienced TD in the past, even if symptoms are currently suppressed or partially suppressed by ongoing metoclopramide use. Reglan's labeling explicitly warns that metoclopramide can cause TD, a syndrome of potentially irreversible and disfiguring involuntary movements (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The drug may also suppress or partially suppress the signs of TD, potentially delaying diagnosis by masking the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This masking effect is a critical safety concern, as it can lead to continued exposure and worsening of the condition before recognition. The labeling further advises avoiding concomitant use of other drugs known to cause TD, and if symptoms occur, discontinuing Reglan and seeking immediate medical attention (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Risk Factors and Clinical Implications

The mechanistic pathway linking Reglan to TD involves chronic blockade of dopamine D2 receptors in the striatum, which leads to compensatory upregulation of dopamine receptors and subsequent supersensitivity. This supersensitivity is thought to underlie the development of involuntary movements. The risk of TD from metoclopramide is influenced by several factors. Data indicate that the overall risk is low, in the range of 0.1% per 1000 patient years, which is far below previously estimated risks of 1%-10% suggested in some treatment guidelines (https://pubmed.ncbi.nlm.nih.gov/31050085/). However, certain populations are at higher risk. Older age is a significant risk factor, with older persons showing increased risk and emergence of TD after shorter treatment durations and lower dosages of DRBAs (https://pubmed.ncbi.nlm.nih.gov/34703232/). High-risk groups also include elderly females, diabetics, patients with liver or kidney failure, and those on concomitant antipsychotic drug therapy, which reduces the threshold for neurological complications (https://pubmed.ncbi.nlm.nih.gov/31050085/). A case report of a postoperative gynecological patient who developed dyskinetic movements after a single intraoperative dose of metoclopramide highlights that even short-term exposure can trigger TD in susceptible individuals, especially when risk factors are present (https://pubmed.ncbi.nlm.nih.gov/34712535/).

Causation Timeline and Documentation Importance

From a causation-focused clinical interpretation, the timeline between Reglan exposure and TD onset can vary widely. While some patients develop TD after months or years of use, others may experience symptoms after only a few doses, particularly if they have underlying risk factors. The condition is often irreversible, emphasizing the importance of early detection and discontinuation of the offending agent. For affected patients, documenting a history of TD with the appropriate ICD-10 code (G24.01) is essential for medical records, as it informs future treatment decisions and avoids re-exposure to DRBAs. The safety communication context around Reglan and TD underscores the need for clinicians to weigh the benefits of metoclopramide against the risk of TD, especially in high-risk populations, and to monitor patients closely for any signs of involuntary movements. In summary, Reglan is a known cause of tardive dyskinesia through its dopamine receptor-blocking mechanism. The risk, while low overall, is elevated in older adults, females, diabetics, and those with renal or hepatic impairment or concurrent antipsychotic use. TD can occur after short or long exposure, and its potentially irreversible nature mandates cautious prescribing and vigilant monitoring. The ICD-10 code for history of tardive dyskinesia (G24.01) is used to document this condition in patients with prior TD episodes, ensuring appropriate medical follow-up and avoidance of future DRBA use.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified medical contexts for case-specific decisions.

Frequently Asked Questions

What is the ICD-10 code for history of tardive dyskinesia?

The ICD-10 code for history of tardive dyskinesia is G24.01. This code is used to document the condition in medical records for patients who have experienced tardive dyskinesia in the past, even if symptoms are currently suppressed or partially suppressed by ongoing metoclopramide use.

Can Reglan cause tardive dyskinesia after short-term use?

Yes, tardive dyskinesia can occur after variable exposure durations, including after a single dose in some cases, particularly in individuals with risk factors such as older age, female gender, diabetes, or renal/hepatic impairment (https://pubmed.ncbi.nlm.nih.gov/34712535/).

What are the risk factors for developing tardive dyskinesia from Reglan?

Risk factors include older age, female gender, diabetes, liver or kidney failure, and concomitant use of antipsychotic drugs. Older persons show increased risk and emergence of TD after shorter treatment durations and lower dosages (https://pubmed.ncbi.nlm.nih.gov/34703232/).

Does submitting information create an medical context-client relationship?

No. Submission requests an initial records screening only and does not create an medical context-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.